Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Chardan Capital to Neutral

Key Points

• Chardan Capital downgraded EyePoint Pharmaceuticals from “buy” to “neutral” and set a $5 price target, implying only 2.67% upside from the stock’s $4.87 price. The broader analyst consensus is “Hold.”
• EyePoint shares have fallen 67%, trading near their 52-week low of $3.95, while the company reported a quarterly loss of $1.09 per share—worse than the expected $1.01 loss.
• The company’s DURAVYU Phase 3 data showed potential treatment-burden benefits, but the full trial missed its primary endpoint because of an unusual vision-loss cohort, increasing regulatory and clinical uncertainty ahead of the second pivotal trial.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) was downgraded by investment analysts at Chardan Capital from a "buy" rating to a "neutral" rating in a research report issued on Tuesday. They currently have a $5.00 price target on the stock. Chardan Capital's price target suggests a potential upside of 2.67% from the stock's current price.

A number of other equities analysts also recently commented on EYPT. HC Wainwright reaffirmed a "neutral" rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Cantor Fitzgerald cut shares of Eyepoint Pharmaceuticals from an "overweight" rating to a "neutral" rating in a research note on Monday. Royal Bank Of Canada restated a "sector perform" rating and set a $5.00 price target on shares of Eyepoint Pharmaceuticals in a report on Tuesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a research report on Friday, July 17th. Finally, Jefferies Financial Group decreased their price objective on Eyepoint Pharmaceuticals to $8.00 and set a "buy" rating on the stock in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $30.11.

Eyepoint Pharmaceuticals Stock Down 67.0%

Shares of NASDAQ:EYPT opened at $4.87 on Tuesday. The business has a fifty day moving average of $13.10 and a two-hundred day moving average of $13.62. The stock has a market cap of $419.84 million, a P/E ratio of -1.30 and a beta of 1.76. Eyepoint Pharmaceuticals has a 52-week low of $3.95 and a 52-week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.08). The company had revenue of $0.51 million for the quarter, compared to analysts' expectations of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. On average, equities analysts anticipate that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Stempoint Capital LP boosted its stake in Eyepoint Pharmaceuticals by 129.1% during the first quarter. Stempoint Capital LP now owns 810,764 shares of the company's stock worth $10,451,000 after buying an additional 456,915 shares during the period. Janus Henderson Group PLC increased its position in shares of Eyepoint Pharmaceuticals by 22.6% during the first quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company's stock valued at $46,419,000 after acquiring an additional 663,439 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Eyepoint Pharmaceuticals by 2,158.3% in the 1st quarter. California State Teachers Retirement System now owns 105,101 shares of the company's stock valued at $1,355,000 after acquiring an additional 100,447 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Eyepoint Pharmaceuticals by 58.4% in the 1st quarter. The Manufacturers Life Insurance Company now owns 36,072 shares of the company's stock worth $465,000 after acquiring an additional 13,297 shares during the last quarter. Finally, Commodore Capital LP acquired a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter worth approximately $36,414,000. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

More Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint said DURAVYU was non-inferior to on-label aflibercept in an ad hoc analysis that excluded an asymmetric cohort of nine patients whose vision loss was considered unrelated to wet AMD. The trial also showed a 42% reduction in treatment burden, strong anatomic control through Week 56, supplement-free treatment rates and a favorable redosing safety profile. EyePoint Announces Topline Data from LUGANO
• Positive Sentiment: Jefferies lowered its price target to $8 but maintained a “buy” rating, while Chardan reaffirmed its “buy” rating and $65 target. These bullish views indicate some analysts believe the LUGANO result may be addressable and that DURAVYU’s longer-duration treatment profile retains value.
• Neutral Sentiment: Trading in EYPT was temporarily halted for pending news before the trial results were released, reflecting the material importance of the announcement. JPMorgan reaffirmed its “neutral” rating.
• Negative Sentiment: The full trial dataset did not meet the primary endpoint because the unusual vision-loss cohort affected the result. Investors now face greater regulatory and clinical uncertainty, particularly while awaiting the second pivotal Phase 3 trial. EyePoint's eye drug misses main goal in late-stage trial
• Negative Sentiment: Cantor Fitzgerald downgraded EyePoint from “overweight” to “neutral.” The setback prompted speculation that competing ophthalmology companies, including Ocular Therapeutix and Forma Therapeutics, may now appear more attractive, further pressuring EYPT’s valuation.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source